Go Premium in Our Biggest Sale Ever

Go Ultimate 75% OFF

GB:0GP7 Stock Latest News

Company AnnouncementsMedivir Granted U.S. Combination Patent for Fostrox Plus Lenvatinib2d ago

Company AnnouncementsMedivir Earnings Call Highlights Funding and Clinical Progress4d ago
Company AnnouncementsMedivir advances liver cancer trial after financing and patent progress1w ago
Company AnnouncementsMedivir Updates Share Structure Following LTIP 2023 Conversion1M ago
Company AnnouncementsMedivir Bolsters Finances as Fostrox and MIV-711 Advance in Key Phase II Programs2M ago

Medivir Expands Share Capital to Fund MIV-711 Orphan Indication

Company AnnouncementsMedivir Expands Share Capital to Fund MIV-711 Orphan Indication3M ago

Company AnnouncementsMedivir Shareholders Approve Directed Issue to Bolster Drug Development3M ago

Company AnnouncementsMedivir secures long-term U.S. patent protection for fostrox–lenvatinib liver cancer combination3M ago

Company AnnouncementsMedivir Expands Share Capital Following First Tranche of Directed Issue4M ago
Company AnnouncementsMedivir Files Disclosure Document for Directed Share Issue on Nasdaq Stockholm4M ago
Company AnnouncementsMedivir Calls Extraordinary General Meeting with Expanded Voting Options4M ago
Company AnnouncementsMedivir Raises SEK 140 Million to Accelerate MIV‑711 Development in Rare Pediatric Disease4M ago

Company AnnouncementsMedivir Plans SEK 130 Million Directed Share Issue to Advance Rare Pediatric Disease Drug4M ago

Company AnnouncementsMedivir’s fostrox combo shows promising liver cancer data in key journal5M ago

Company AnnouncementsMedivir Begins Key Phase 2 Trial of Fostrox Combo in Advanced Liver Cancer5M ago

Company AnnouncementsMedivir AGM Backs Board, Extends Capital Mandate and Adopts New Incentive Plan6M ago
Company AnnouncementsMedivir Strengthens Finances and Pipeline as Key Cancer and Bone Programs Advance6M ago
Company AnnouncementsMedivir targets Asian partnerships as it showcases liver cancer and bone disease drugs6M ago
Company AnnouncementsMedivir Delays Q1 Report as South Korea Liver Cancer Trial Expands6M ago

Company AnnouncementsMedivir Calls 2026 AGM, Details Shareholder Voting Procedures and Capital Structure7M ago

Company AnnouncementsMedivir sharpens focus on late-stage liver cancer and rare bone disease programs7M ago

Company AnnouncementsMedivir forms elite expert council to drive MIV-711 push in brittle bone disease7M ago